We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RAND:EURONEXT AMSTERDAMRandstad NV Analysis

Data as of 2026-03-14 - not real-time

$11.36

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Rand Capital trades around $11.36, comfortably above its short‑term support of $10.76 yet well below the 30‑day DCF fair value of $37.44, flagging a substantial undervaluation. Technical signals are mixed: the 20‑day SMA (11.48) sits just above price, the 50‑day SMA (11.36) aligns with the market, and the MACD histogram is marginally positive, suggesting a faint bullish bias, while the RSI at 47 indicates neutral momentum. Fundamentals are strained with a –39.9% revenue decline, negative profit margin (‑124%) and trailing EPS of –4.25, though the company holds $4.21 M in cash, carries no debt, and pays a 10.2% dividend yielding a 51% payout ratio. Volume is trending upward, volatility is high at 41% over 30 days, and beta is low (0.25), implying market‑wide moves have limited impact but the stock is nonetheless price‑sensitive.
Given the disparity between market price and intrinsic valuation, the high dividend yield, and the low beta, the stock presents a speculative upside play, but the negative earnings, free‑cash‑flow shortfall, and historic drawdown of over 50% temper enthusiasm. Investors should weigh the attractive yield against sustainability concerns and the company’s uncertain path to profitability before committing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near immediate support
  • Bullish MACD crossover
  • Elevated dividend yield

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF fair value far exceeds market price
  • Increasing trading volume
  • Low beta reducing market‑wide volatility exposure

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Significant valuation gap
  • Negative earnings and free‑cash‑flow pressure
  • High historical drawdown and liquidity constraints

Key Metrics & Analysis

Financial Health

Revenue Growth-39.90%
Profit Margin-124.17%
ROE-13.68%
ROA5.37%
P/B Ratio0.6
Op. Cash Flow$11.3M
Free Cash Flow$-1786764
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI47.3
Support$10.76
Resistance$12.27
MA 20$11.48
MA 50$11.36
MA 200$14.26
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value$37.44
GradeUndervalued
TypeValue
Dividend Yield10.21%

Risk Assessment

Beta0.25
Volatility41.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.